Sanofi, a global and diversified healthcare leader, has announced the start of the first phase of local generic medicines production through Dubai-based Globalpharma at a special ceremony today (October 28).

The announcement follows the recent acquisition of a significant stake in Globalpharma by Sanofi from Dubai Investments (DI), a leading investment company listed on the Dubai Financial Market [DFM].

Dr Amin Hussain Al Amiri, assistant undersecretary for Public Health and Licensing sector at UAE’s Ministry of Health, said: “The healthcare landscape in the UAE is fast evolving and we are working closely with pharmaceutical companies to make UAE the regional hub, which will positively impact the supply, distribution and pricing of drugs.

“The integration of Globalpharma as a Sanofi Company is a landmark milestone in the regional pharmaceutical landscape and will serve the needs of the industry in an effective way.”

Following the completion of the acquisition of a significant stake, announced in June, Globalpharma is being integrated as a Sanofi Company to become the platform to manufacture and promote the generics portfolio of Sanofi in Middle East markets.

The wide portfolio will include anti-infective, cardiovascular and gastrointestinal products.

Antoine Ortoli, senior vice president – Intercontinental Global Operations at Sanofi, said: “Acquiring a significant stake in Globalpharma is in line with our global objective to expand our footprint through innovative business models. Our combined strong geographical presence and portfolios in specific therapeutic areas will enable us to broaden our reach and strengthen our presence in the generics market, providing more patients with high quality, affordable medications.”

Sanofi will bring to Globalpharma its knowledge in industrial development and manufacturing and together with the local Globalpharma team will drive all technology subjects and implementation focused on patients’ needs, said the statement.

Khalid Bin Kalban, managing director and CEO of Dubai Investments, said: “We are excited about this integration of Globalpharma as a Sanofi company which will go a long way in building the company’s capabilities in the region.

“This divestment of shares with Sanofi is a major step forward in strengthening the company’s market leadership through a differentiated and specialty-driven generics portfolio, bringing together the strong reputation of Globalpharma and the global expertise of Sanofi, and tailored to meet the needs and demands of the regional healthcare industry.” - TradeArabia News Service